Sandborn WJ - Search Results

1

Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis.

Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K. Sandborn WJ, et al. J Crohns Colitis. 2019 Feb 1;13(2):172-181. doi: 10.1093/ecco-jcc/jjy149. J Crohns Colitis. 2019. PMID: 30285104 Free PMC article. Clinical Trial.

2

Is antibody testing for inflammatory bowel disease clinically useful?

Panaccione R, Sandborn WJ. Panaccione R, et al. Among authors: sandborn wj. Gastroenterology. 1999 Apr;116(4):1001-2; discussion 1002-3. doi: 10.1016/s0016-5085(99)70087-9. Gastroenterology. 1999. PMID: 10092326 No abstract available.

3

The appendix in ulcerative colitis: a not so innocent bystander.

Panaccione R, Sandborn WJ. Panaccione R, et al. Among authors: sandborn wj. Gastroenterology. 1999 Jul;117(1):272-3. doi: 10.1016/s0016-5085(99)70581-0. Gastroenterology. 1999. PMID: 10381940 No abstract available.

4

Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis.

Louvet B, Buisine MP, Desreumaux P, Tremaine WJ, Aubert JP, Porchet N, Capron M, Cortot A, Colombel JF, Sandborn WJ. Louvet B, et al. Among authors: sandborn wj. Inflamm Bowel Dis. 1999 Aug;5(3):174-81. doi: 10.1097/00054725-199908000-00005. Inflamm Bowel Dis. 1999. PMID: 10453373 Clinical Trial.

5

Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients.

Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Ricart E, et al. Among authors: sandborn wj. Am J Gastroenterol. 2001 Mar;96(3):722-9. doi: 10.1111/j.1572-0241.2001.03612.x. Am J Gastroenterol. 2001. PMID: 11280541

6

Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease.

Sandborn WJ, Loftus EV Jr, Colombel JF, Fleming KA, Seibold F, Homburger HA, Sendid B, Chapman RW, Tremaine WJ, Kaul DK, Wallace J, Harmsen WS, Zinsmeister AR, Targan SR. Sandborn WJ, et al. Inflamm Bowel Dis. 2001 Aug;7(3):192-201. doi: 10.1097/00054725-200108000-00003. Inflamm Bowel Dis. 2001. PMID: 11515844

7

Management of Crohn's disease of the ileoanal pouch with infliximab.

Colombel JF, Ricart E, Loftus EV Jr, Tremaine WJ, Young-Fadok T, Dozois EJ, Wolff BG, Devine R, Pemberton JH, Sandborn WJ. Colombel JF, et al. Among authors: sandborn wj. Am J Gastroenterol. 2003 Oct;98(10):2239-44. doi: 10.1111/j.1572-0241.2003.07675.x. Am J Gastroenterol. 2003. PMID: 14572574

8

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.

Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. Colombel JF, et al. Among authors: sandborn wj. Gastroenterology. 2004 Jan;126(1):19-31. doi: 10.1053/j.gastro.2003.10.047. Gastroenterology. 2004. PMID: 14699483

9

Medical therapy of Crohn disease.

Panaccione R, Sandborn WJ. Panaccione R, et al. Among authors: sandborn wj. Curr Opin Gastroenterol. 2004 Jul;20(4):351-9. doi: 10.1097/00001574-200407000-00009. Curr Opin Gastroenterol. 2004. PMID: 15703664

10

Natalizumab induction and maintenance therapy for Crohn's disease.

Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P; International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Sandborn WJ, et al. N Engl J Med. 2005 Nov 3;353(18):1912-25. doi: 10.1056/NEJMoa043335. N Engl J Med. 2005. PMID: 16267322 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

946 results

Search Page